A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

Who can join: Ages 12 to 45, have obesity, BMI 35+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4.8 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor University of Colorado, DenverDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 120

What this study is for

Primary condition: Obesity/Therapy.

Full scientific study title: Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity.

Who can join

Age12 to 45SexAnyBMI35 or higher

Ages 12 to 45, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

English-speaking
male or female (sex assigned at birth)
12-18 y/o with obesity (BMI\>120% of the 95th %ile)
30-45 y/o with obesity (BMI\>35 kg/m2)

Key exclusion criteria

treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months
currently taking anti-psychotic medications (anti-depressants accepted)
diagnosis of type 2 diabetes
current or lifetime anorexia nervosa or current bulimia nervosa
head injury resulting in loss of consciousness \>30min

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Colorado1 site

University of Colorado Anschutz Medical Campus
Aurora, Colorado
Allison Shapiro, PhD, MPH303-724-3733allison.shapiro@cuanschutz.edu

Follow this trial

We email you if NCT07021937 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Scheduled start: June 15, 2026. Expected completion: April 30, 2031. Last updated on ClinicalTrials.gov: July 2, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.